Table 4.

Cohort 2: Unadjusted and Adjusted Risk Ratios Comparing Antiretroviral Therapy Regimens for Hypertensive Disorders of Pregnancy Outcomes Among Pregnant Women Living With Human Immunodeficiency Virus Who Delivered at Grady Memorial Hospital From 2011–2018

	INSTI-Containing vs PI-Containing Regimens		NNRTI-Containing vs PI-Containing Regimens		ART Initiation in Pregnancy vs Before Pregnancy [Adjusted RR (95% CI)]
Outcome	RR (95% CI)	Adjusted RR (95% CI)	RR (95% CI)	Adjusted RR (95% CI)		P-Interaction
HDP*	2.6 (1.4–4.8)	2.8 (1.5–5.1)	2.5 (1.1–5.7)	2.9 (1.2–6.9)	1.5 (0.8–2.7)	.839
Gestational hypertension	2.6 (1.2–5.4)	2.7 (1.3–5.9)	2.5 (1.0–6.8)	3.2 (1.1–9.0)	1.5 (0.7–3.3)	.993
Preeclampsia	2.6 (0.9–7.6)	2.6 (0.9–7.3)	2.0 (0.4–9.8)	2.1 (0.4–10.6)	1.6 (0.5–4.9)	†

INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy; RR, risk ratio; HDP, hypertensive disorders of pregnancy.

All multivariate models adjusted for age, race, illicit drug use, and initiation of ART or new ART regimen during pregnancy.

Eighteen women are excluded from this analysis for missing race (n=15) or timing of ART initiation (n=3) data.

^*Gestational hypertension, preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.

^†Model with interaction term failed.